Azathioprine is one of the most widely used drugs for keeping Crohn’s disease in remission once a flare has been controlled. It has been part of the inflammatory bowel disease toolkit for decades, first borrowed from transplant medicine where it was used to prevent organ rejection. A Cochrane review found that it roughly doubles the odds of staying in remission compared to placebo, with a number needed to treat of seven, meaning about one in every seven patients who takes it will benefit beyond what they would get from a dummy pill.1PubMed. Azathioprine for maintaining remission of Crohn’s disease But azathioprine comes with a slow onset, a real side-effect profile, and a level of genetic and metabolic complexity that makes it a drug worth understanding before starting.
How Azathioprine Works in Crohn’s Disease
Azathioprine is a prodrug, meaning your body converts it into its active form after you swallow it. It gets broken down into 6-mercaptopurine and then into compounds called 6-thioguanine nucleotides, which interfere with the way rapidly dividing immune cells copy their DNA. The practical result is that overactive immune cells, particularly certain types of T cells driving the gut inflammation in Crohn’s, are pushed toward self-destruction. Research has shown that azathioprine selectively depletes a specific subset of memory T cells that are heavily activated in Crohn’s disease, which helps explain why the drug calms intestinal inflammation without completely shutting down the immune system.2JCI Insight. Azathioprine therapy selectively ablates human Vδ2+ T cells in Crohn’s disease
The drug also has a steroid-sparing effect. That same Cochrane review found strong evidence that patients on azathioprine needed fewer corticosteroids to stay well, with a number needed to treat of just three for patients with quiescent disease.3PubMed. Azathioprine for maintaining remission of Crohn’s disease For anyone who has dealt with the side effects of long-term steroids, from weight gain to bone thinning to mood swings, this is one of azathioprine’s most valuable properties.
The Slow Start
One of the most frustrating aspects of azathioprine is that it does not work quickly. The drug has long been recognized as having a prolonged time to response.4Gastroenterology. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn’s disease Most clinicians advise patients to expect at least three months before the drug reaches its full effect, and it can take even longer. This means azathioprine is not a rescue drug for active flares. During those early weeks, patients typically need another therapy, often corticosteroids, to bridge the gap. The wait can feel discouraging, particularly for someone who is symptomatic, but knowing this timeline in advance helps set realistic expectations.
Long-Term Remission and What to Expect
The long-term track record for azathioprine is encouraging but not overwhelming. A large prospective study following patients over many years found that the cumulative rate of sustained remission ten years after starting azathioprine was about 38%. During the follow-up period, which spanned nearly two thousand patient-years of observation, active disease accounted for fewer than one in five patient-years.5Clinical Gastroenterology and Hepatology. Long-term Outcome of Patients With Crohn’s Disease Who Respond to Azathioprine Those numbers tell a nuanced story: azathioprine helps many people stay well for years, but a substantial portion will eventually relapse or need to escalate therapy. It is better understood as a durable maintenance option than as a cure.
Combination with Biologic Therapy
A landmark trial published in the New England Journal of Medicine tested whether combining azathioprine with infliximab, one of the first biologic drugs approved for Crohn’s, was better than using either drug alone. The results were clear. At six months, about 57% of patients on the combination were in steroid-free remission, compared with roughly 44% on infliximab alone and 30% on azathioprine alone. Mucosal healing, where the intestinal lining actually looks normal on endoscopy, showed an even starker pattern: about 44% with combination therapy versus around 17% with azathioprine by itself.6PubMed. Infliximab, azathioprine, or combination therapy for Crohn’s disease
These results changed how many gastroenterologists approach treatment, particularly for patients with moderate-to-severe disease. Azathioprine alone remains a reasonable option for people with less aggressive disease or those who prefer to avoid biologics, but the combination approach has become standard for many newly diagnosed patients who need early, aggressive control.
Genetic Testing Before Starting
Not everyone metabolizes azathioprine the same way, and the consequences of getting unlucky can be serious. Two enzymes are particularly important: TPMT and NUDT15. People who carry genetic variants that reduce the activity of either enzyme end up with dangerously high levels of the drug’s active metabolites, which can wipe out white blood cells. A real-world study found that patients with poor or intermediate TPMT or NUDT15 metabolizer status were nearly three times as likely to stop azathioprine due to bone marrow toxicity compared to normal metabolizers.7PubMed Central. TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease
The importance of these two genes varies by ancestry. TPMT variants are more common in people of European descent, and testing for TPMT has been standard practice in many Western countries for years. But in East Asian populations, TPMT variants are rare and do a poor job predicting who will get into trouble. Instead, a variant in NUDT15 turned out to be the critical factor. A study in Korean patients with Crohn’s disease found that NUDT15 variant carriers had dramatically higher rates of severe early white blood cell drops, with all patients who were homozygous for the variant developing severe leukopenia within about four weeks.8PLOS ONE. Measurements of 6-thioguanine nucleotide levels with TPMT and NUDT15 genotyping in patients with Crohn’s disease The practical takeaway is that genotyping for both TPMT and NUDT15 before prescribing azathioprine is now recommended, and results should guide the starting dose or, in some cases, steer the clinician toward a different drug entirely.
Monitoring Drug Levels
Even with genetic testing upfront, azathioprine metabolism varies enough from person to person that many gastroenterologists use therapeutic drug monitoring to fine-tune doses. This involves measuring levels of two metabolites in red blood cells: 6-thioguanine nucleotides (6-TGN), the active compound you want, and 6-methylmercaptopurine (6-MMP), a byproduct linked to liver toxicity. When 6-TGN levels are too low, the drug is not working well; when 6-MMP levels are too high, there is a risk of liver damage without much therapeutic benefit.9PubMed. Thiopurine metabolite ratios for monitoring therapy in pediatric Crohn disease
Some patients turn out to be “shunters,” meaning their metabolism preferentially channels the drug toward 6-MMP rather than 6-TGN. These individuals get all the side effects and little of the benefit. Metabolite monitoring can identify them, and in many cases the problem can be solved by lowering the azathioprine dose and adding allopurinol, a drug normally used for gout, which redirects metabolism back toward the therapeutic pathway. Monitoring also helps catch non-adherence: if someone says they are taking the drug but metabolite levels are undetectable, the conversation shifts from dose adjustment to understanding what barriers the patient is facing.10Journal of Pharmacology and Pharmacotherapeutics. Exposure to Azathioprine Metabolites and Clinical Outcome in Indian Patients with Crohn’s Disease
The Allopurinol Strategy
The combination of low-dose azathioprine with allopurinol has become an increasingly popular rescue strategy for patients whose metabolite profiles show excessive 6-MMP production. A study in IBD patients showed that combining just 50 mg of azathioprine with 50 mg of allopurinol was enough to achieve adequate 6-TGN levels in most patients, while normalizing 6-MMP and liver enzymes.11PubMed. Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations This approach requires careful monitoring, since allopurinol dramatically boosts the potency of azathioprine, but it can salvage therapy in people who would otherwise need to abandon the drug.
Side Effects Worth Knowing About
Azathioprine’s side-effect profile falls into a few distinct categories that behave differently and warrant different responses.
Pancreatitis
Drug-induced pancreatitis is one of the more alarming early side effects. A prospective study found it occurred in about 7% of patients, typically within the first three weeks of starting the drug. Close to half of those affected needed hospitalization, though the episodes were generally mild and resolved after stopping azathioprine. Smoking was the strongest risk factor.12PubMed Central. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases—A Prospective Study on Incidence and Severity A systematic review that pooled data across multiple trials found a somewhat lower incidence of about 4%, but regardless of the exact number, pancreatitis is an idiosyncratic reaction, meaning it is not dose-dependent. If it happens, azathioprine has to be stopped permanently, and switching to 6-mercaptopurine is usually not safe either, since the two drugs share this risk.13Frontline Gastroenterology. Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn’s disease: a systematic review
Bone Marrow Suppression
A low white blood cell count is the side effect clinicians monitor for most aggressively. A study spanning 27 years of experience found that leukopenia occurred in about 4% of patients on azathioprine for inflammatory bowel disease. In severe cases, it can lead to life-threatening infections. Two patients in that long-term cohort died from sepsis related to pancytopenia.14PubMed Central. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience This risk is largely why genetic testing and regular blood count monitoring are so important. Bone marrow suppression is dose-dependent and often reversible if caught early.
Nausea and Flu-Like Symptoms
Nausea is actually the most common reason people stop taking azathioprine, affecting about 12% of patients in prospective studies.15PubMed Central. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases—A Prospective Study on Incidence and Severity Some patients also experience flu-like symptoms, joint aches, or general malaise. These are sometimes manageable by taking the drug at bedtime, splitting the dose, or switching to 6-mercaptopurine, but for some people the intolerance is bad enough to warrant changing drugs.
Cancer Risk with Prolonged Use
The question of cancer risk is one that weighs on many patients taking azathioprine long term. A large Danish nationwide cohort study found that current thiopurine users had a modestly elevated cancer risk compared to people with IBD who had never used the drug, with an adjusted hazard ratio of about 1.36 for those on thiopurine monotherapy. When thiopurines were combined with biologic therapy, the risk was higher, roughly two and a half times that of never-users. Specific cancer types linked to thiopurine monotherapy included urinary tract, digestive organ, female genital organ, and non-melanoma skin cancers. The elevated overall risk persisted even when patients were followed for more than five years.16Clinical Gastroenterology and Hepatology. Thiopurines and the Risk of Cancer in Patients With Inflammatory Bowel Disease and Reference Individuals Without Inflammatory Bowel Disease
Context matters here. The absolute risk increase is small for most individuals, and untreated or poorly controlled Crohn’s disease carries its own cancer risk, particularly colorectal cancer. Still, the skin cancer association is well enough established that dermatologist screening and sun protection are standard advice for anyone on long-term azathioprine.
What Happens When You Stop
Deciding when, or whether, to stop azathioprine is one of the trickier judgment calls in Crohn’s management. A randomized controlled trial compared patients who continued azathioprine after more than two years of remission to those who were switched to placebo. Among those who kept taking the drug, 85% stayed in remission over the following year, compared to just 47% who stopped. In patients who had been on higher doses, the gap was even wider: 89% versus 33%.17PubMed. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn’s disease: increased relapse rate the following year These numbers make a strong case for continuing the drug as long as it is tolerated, but they have to be weighed against the cumulative side-effect and cancer risks discussed above. This is a conversation that tends to come up every few years between patients and their gastroenterologists, and the right answer depends on disease severity, risk factors, and individual preferences.
Azathioprine Versus Methotrexate
For patients who cannot tolerate azathioprine, methotrexate is the main alternative immunomodulator. Head-to-head comparisons suggest the two drugs have similar remission rates: one randomized trial found no significant difference at either three or six months, with azathioprine achieving remission in about 63% of patients and methotrexate in about 56% at the six-month mark.18PubMed. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s disease However, methotrexate caused more bothersome side effects like fatigue, nausea, and vomiting in that study. On the other hand, a prospective comparison that looked specifically at mucosal healing found that azathioprine achieved endoscopic healing in half of patients, compared to only about one in nine on methotrexate.19PubMed. Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab A key practical difference is that methotrexate is strictly contraindicated in pregnancy, while azathioprine is considered reasonably safe, which can be a decisive factor for people of childbearing age.
Pregnancy and Breastfeeding
Anxiety about taking an immunosuppressant during pregnancy is entirely understandable, but the evidence on azathioprine is reassuring. Expert panels and review articles consistently classify azathioprine as reasonably safe during pregnancy, with only a small number of discordant findings.20Digestion. Pregnancy and Breastfeeding in Patients with Crohn’s Disease A multidisciplinary international expert panel went further, stating that azathioprine may be administered safely during pregnancy and in patients wishing to conceive.21Journal of Crohn’s and Colitis. Appropriate management of special situations in Crohn’s disease The general consensus is that active Crohn’s disease during pregnancy poses a greater risk to both mother and baby than the drug itself. During breastfeeding, azathioprine is also considered probably safe, with minimal drug levels detected in breast milk.
After Surgery
Many patients with Crohn’s disease eventually need surgery to remove a damaged section of bowel, and the disease has a frustrating tendency to recur at the surgical site. Azathioprine has been studied specifically for preventing this. Starting it soon after surgery appears to delay and reduce recurrence. A study comparing different approaches to post-operative prophylaxis found that both immediate azathioprine and endoscopy-driven azathioprine, where the drug is started only if early signs of recurrence appear on a follow-up scope, significantly reduced the need for repeat surgery compared to waiting until symptoms returned.22PubMed. Immediate prophylactic vs endoscopic or symptomatic-driven azathioprine treatment to prevent surgical recurrence after intestinal resection for Crohn’s disease Interestingly, the immediate and endoscopy-driven strategies performed similarly, suggesting that a reasonable approach for lower-risk patients is to scope a few months after surgery and start azathioprine only if inflammation is already appearing.
Use in Children
Azathioprine is used in pediatric Crohn’s disease as well, often started early after diagnosis to spare children from prolonged steroid courses that can stunt growth. A study of over 100 children receiving azathioprine at relatively high doses found that only two had to stop the drug due to persistent side effects, and there was a trend toward better growth in the treated group.23PubMed. High-dose azathioprine in children with inflammatory bowel disease Growth improvement is a meaningful outcome in pediatric IBD, since chronic inflammation and steroids both interfere with normal development. The side-effect profile in children is broadly similar to adults, and the same genetic testing and metabolite monitoring apply.
Vaccines and Azathioprine
Because azathioprine dampens the immune system, it can blunt your response to vaccines. A study looking at hepatitis B vaccination found that patients who were already on azathioprine when vaccinated had a significantly weaker antibody response: only 55% developed adequate antibodies, compared to 88% of those vaccinated before starting the drug. In a multivariable analysis, azathioprine use was independently associated with a weaker vaccine response.24PubMed. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients The picture is not uniformly bleak, though. A prospective study of pneumococcal vaccination found that azathioprine alone did not significantly reduce the response rate compared to patients on mesalamine.25PubMed. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study The impact seems to vary by vaccine type. The practical implication is that ideally, major vaccinations, particularly hepatitis B, should be completed before starting azathioprine whenever possible. Live vaccines are generally contraindicated while on the drug.
Adherence and What Drives It
Taking a medication every day for years, especially one that does not produce immediately noticeable benefits and comes with a list of concerning possible side effects, is harder than most people admit. A small study of Crohn’s patients in long-term remission on azathioprine found that about three-quarters were not fully adherent to their prescribed dose.26Inflammatory Bowel Diseases. How Adherent to Treatment With Azathioprine Are Patients With Crohn’s Disease in Long-term Remission? What makes that finding striking is that it did not seem to affect short-term outcomes in that particular study, which may itself reinforce the temptation to skip doses.
More compellingly, a larger study showed that patient education programs specifically about azathioprine, covering both its benefits and its risks, improved adherence and reduced endoscopic relapse rates. Non-adherent patients who went through the educational program had a relapse rate of about 16%, compared to about 30% in non-adherent patients who did not participate.27PubMed Central. Patients’ Educational Program Could Improve Azathioprine Adherence in Crohn’s Disease Maintenance Therapy Beliefs about the drug’s necessity and concerns about its safety were the biggest drivers of non-adherence, suggesting that honest, detailed conversations with a gastroenterologist or IBD nurse about why the drug is being used and what to realistically expect from side effects can make a tangible difference in how well the drug works in practice.
Effects on Gut Bacteria
An emerging area of interest is how azathioprine interacts with the gut microbiome. A study examining the mucosa-associated bacteria in Crohn’s patients found that azathioprine treatment was associated with increases in certain beneficial bacterial groups, including Roseburia and Ruminococcaceae, while decreasing Fusobacteriaceae, a family of bacteria that has been linked to intestinal inflammation.28PubMed Central. Characteristics of mucosa-associated gut microbiota during treatment in Crohn’s disease Whether these microbial shifts are a cause of the drug’s benefit, a consequence of reduced inflammation, or both, is not yet clear. But it adds another layer to understanding what azathioprine is doing beyond simply suppressing immune cells, and it points toward a future where microbiome monitoring might help guide treatment decisions.